Full-Time
Advanced cancer detection using DNA analysis
$320k - $370k/yr
Expert
Palo Alto, CA, USA
Hybrid
1-2 designated in-office working days each week for employees who live within 50 miles of Palo Alto, CA or Baltimore, MD offices.
Delfi Diagnostics focuses on early cancer detection using advanced machine learning and fragmentomics, which involves analyzing fragments of cell-free DNA. Their technology differs from traditional methods by scanning millions of data points to find previously unrecognized cancer-associated fragments, allowing for a more comprehensive detection of cancer. The team includes experts in cancer biology, bioinformatics, and machine learning, led by Dr. Victor Velculescu, a recognized figure in genomics. Delfi's business model is based on providing their cancer detection services to healthcare providers and patients, aiming to improve the efficiency and effectiveness of cancer screening.
Company Size
51-200
Company Stage
Series B
Total Funding
$330.5M
Headquarters
Baltimore, Maryland
Founded
2019
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Parental Leave
Flexible Time Off
Paid Holidays
Dr. Amoolya Singh Honored as Exceptional Business Leader by San Francisco Business TimesBALTIMORE and PALO ALTO, Calif., May 12, 2025 /PRNewswire/ -- DELFI Diagnostics, Inc ., developer of innovative blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer detection and monitoring, today announced that its Chief Technology Officer, Dr. Amoolya Singh , has been named to the San Francisco Business Times' 2025 Most Influential Women in Bay Area Business list. Dr. Singh, who was previously named to this list in 2021, joined DELFI in December 2024 and has over two decades of experience working at the intersection of biotechnology and computational science. She boasts an impressive track record of developing breakthrough genomic technologies and products
DELFI also launched the DELFI-TF Assay and related services to help actively guide critical oncology drug development decisions for pharmaceutical companies.
Fragmentomics pioneer showcases DELFI-TF treatment monitoring solution alongside early detection capabilities at a premier oncology research eventBALTIMORE and PALO ALTO, Calif., April 25, 2025 /PRNewswire/ -- DELFI Diagnostics, Inc ., developer of innovative blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer detection and monitoring, today announced its team is presenting at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL. DELFI is showcasing its groundbreaking DELFI-TF technology for treatment response monitoring alongside its early detection capabilities."Our presentations at AACR highlight how DELFI's fragmentomics platform is transforming both early cancer detection and treatment monitoring," said Victor E. Velculescu, MD, PhD, DELFI Diagnostics Founder and Board Director. "The DELFI technology represents a paradigm shift in how we detect cancer by combining genome-wide fragmentomics of DNA in the blood with AI algorithms for high sensitivity in the screening setting as well as for noninvasively measuring treatment efficacy in advanced cancer patients. "DELFI is presenting multiple podium and poster sessions at AACR, including:Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection presented by Victor E. Velculescu, MD, PhDTuesday, April 29 , 11:06 AM - 11:26 AM CT, Room S100 BC (Grand Ballroom BC) - McCormick Place SouthLeveraging the cfDNA fragmentome to predict immunotherapy response presented by Valsamo Anagnostou, MD, PhDMonday, April 28 , 3:05 PM - 3:20 PM CT, Room S105 - McCormick Place SouthAnalysis of lung cancer clinical characteristics using cell-free DNA fragmentomes presented by Lorenzo Rinaldi, PhDMonday, April 28 , 9:00 AM - 12:00 PM CT, Section 28, Poster 29Cell-free DNA fragmentomes for treatment response monitoring in patients with metastatic colorectal cancer: the DOLPHIN study presented by Denise E
Canton-based Delfi Diagnostics has named Robert Guigley as its new chief commercial officer.
DELFI Diagnostics working with Incendia Therapeutics to employ advanced treatment monitoring test in a Phase 1 clinical trial.